Dyne Therapeutics expects to net $305M in stock sale: The company on Monday dropped updated stock-moving results for its myotonic dystrophy type 1 and Duchenne muscular dystrophy therapies. With the proceeds, Dyne expects it can fund operations into the second half of 2026, according to an SEC filing. — Lei Lei Wu
Nanobiotix pushes back readout for head and neck cancer drug: The biotech now plans to present interim Phase 3 data for its Johnson & Johnson-partnered radioenhancer in the first half of 2026. It had originally planned to share data in mid-2025. The delay comes as the companies laid out plans to forgo a futility analysis and conduct an intern analysis only after the final patient is recruited. — Ayisha Sharma